Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Retinitis pigmentosa (RP) is a term for a group of eye diseases that can lead to loss of sight. What they have in common are specific changes your doctor sees when they look at your retina – a ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

NEWPORT BEACH, Calif., August 18, 2025--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated ...

Treatment With 9-cis Beta-Carotene-Rich Powder in Patients With Retinitis Pigmentosa: A Randomized Crossover Trial Rotenstreich Y, Belkin M, Sadetzki S, et al. JAMA Ophthalmol. 2013;131:985-992.

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

This work can be read in the journal PLOS Biology. Retinitis pigmentosa is the most common hereditary retinal disease in humans, with a prevalence of one in every 4,000 people worldwide.

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

Retinitis pigmentosa is an eye disease in which there is damage to the retina. Approximately 2 million individuals (about 1 in 4,000) worldwide are affected by the condition, which typically ...